Get started
TEVA PHARMA INDTEVA PHARMA INDTEVA PHARMA IND

TEVA PHARMA IND

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

TEV trade ideas

TEVA WINS FDA APPROVAL - EPIPEN FOR PEDIATRIC CHILDRENA MUST READ ARTICLE!! The FDA Approval is "NOT" just for adults. FDA also gave TEVA approval to administer the EPIPEN to PEDIATRIC CHILDREN arstechnica.com Pediatric Sub-population Approximate Age Range Newborn - birth to 1 month of age Infant - 1 month to 2 years of age Child - 2 to 12 years of age Adolescent - 12-21 years of age This opens up a whole new Sales Market / Revenue Stream for TEVA and the Generic Epipen. FOOD ALLERGY RESEARCH GROUP (FARE) How Many People Have Food Allergies? Researchers estimate that up to 15 million Americans have food allergies, including 5.9 million children under age 18. That’s 1 in 13 children, or roughly two in every classroom. About 30 percent of children with food allergies are allergic to more than one food. Food Allergies Are on the Rise The Centers for Disease Control & Prevention reports that the prevalence of food allergy in children increased by 50 percent between 1997 and 2011. Between 1997 and 2008, the prevalence of peanut or tree nut allergy appears to have more than tripled in U.S. children.
NYSE:TEVALong
by UnknownUnicorn3159981
5
TEVA is recharging the battery waiting next earnings release ($TEVA) was accelerating the uptrend but since some days it has come back on its path inside a bullish flag. It is important to note that next week earnings will be released so high volatility should be expected. Masch is about to turn on bullish mode RSI is quite down and vortex is neutral. I might expect that some investors will get long before the earnings pushing the price up but it is just an hypothesis. So far we are still inside the range with lower and upper edges showed on the chart.
NYSE:TEVA
by TRADOMICS_
TEVA up trend is acceleratingAs showed in the picture trend is accelerating as a sign of streght for TEVA. After some consolidation pauses we have a situation where RSI in pointing up, MACD non really clear as we have had a lateral movement, volatility stop positive. Red trendline is showing the acceleration. TP around 27 first and 30 dollars after. Despite some up and down of nasdaq, Teva has held the hit continuing the lateral movement rather than going down, another sign of strenght at the moment.
NYSE:TEVALong
by TRADOMICS_
$TEVA - Berkshire breakout? Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised this week: fortune.com markets.businessinsider.com finance.yahoo.com Just after Buffet disclosed the position, Teva announced the U.S. release of the QVAR Redihaler Inhalation Aerosol. www.streetinsider.com -new form of asthma inhalation treatment -breath actuated I don't think this is too important. I'd much rather to follow his other position into AAPL rather than TEVA
NYSE:TEVA
by UnknownUnicorn2421992
1
LONG $TEVAFrom looking at the chart patterns, I believe we will see a somewhat classic cup and handle pattern into the next few months. I am anticipating an upward breakout trend now that WB has increased his stake in the company and increases shareholder confidence . After consecutive bad earnings reports I believe this company will recover due to the modest estimates for next quarter. I also think analysts will increase their one year price targets once they have a positive earnings report. In my opinion a good buy and will be buying in next week after markets close Tuesday.
NYSE:TEVALong
by goodppldonttrade
Teva is now a buyAfter a couple of years where price has persistently followed the downtrend, last week Teva broke up such dynamic hreshold. Price has confirmed such trendline with a hammer 3 days ago at 17.04 dollars. Moreover we have the cross on the daily pattern between MA 50 and MA 200 turning to bullish set-up. Q1 earnings has been released beating expectations. SAR is positive and supertrend recently turned into bullish conformation as well. Trump is due to talk about drug prices this week but I don't deem Teva will be harshly impacted, because of the type of business. On a daily basis the hammer of three days ago confirmed by two green candles bear witness to a short term reversal. TP around 21.50/21.80
NYSE:TEVALong
by TRADOMICS_
TEVA Bullish bat pattern and demand zone before ERTEVA usually has HUGE move on its earning release day, which is 5/2. Here we got an bullish bat pattern but it's still way too far from the entry, while with regard to the potential huge move, it worth noticing beforehand and if it actually got crashed all the way there, it could be a high-risk high-reward trade! To start this trade ,there are 2 conditions to match 1. It gets slumped after ER 2. There are reversal signs between 11.50-12.00 Although it's still too early for this plan, but it doesn't hurt to make trading plans!! Let's see how it goes!
NYSE:TEVALong
by Trader_Joe_Lee
TEVA: Potential Value BuyPotential Buy opportunities are identified by the price levels at 16.75 / 14.75 (USD) Bullish Target (Long Term) 34.75 Berkshires average price is likely around 16.50~17 Research Sector: Pharma Publically Disclosed February 15 that Berkshire Hathaway bought shares but it is unclear exactly when they purchased 18,875,721 shares of the company when the price averaged around $15. The $357.7 million stake represents 1.86% of the company and merely 0.19% of the portfolio (4th Quarter 2017) In another 2017 development, Teva suspended its dividend. A cessation of shareholder payouts, dire results and heavy debt prompted the market to run from the stock. TEVA develops, manufactures and sells generic medicine in a range of forms including tablets, capsules, injectables, inhalants, liquids, oitments and creams. They also create specific specialty medicines that assist the Central Nervous System and Respiratory medicines focused on asthma and chronic obstructive pulmonary disease. One of their primary drugs is Copaxone.. used to treat multiple sclerosis however we are seeing more and more generic competition come into the marketplace Teva’s new Chief Executive Officer Kare Schultz laid out a vast cost-cutting plan in December, halting dividend payments and eliminating 25% of the global workforce. He has repeatedly stated that his biggest priority is to curb the company’s $31.4 billion debt pile.. Other Resources www.forbes.com Announcement of new asthma drug www.streetinsider.com Trading can contain substantial risk and is not suited for every investor. An investor could potentially lose all or more than their initial investment. "Risk capital" - is money that can be lost without jeopardizing ones financial security or life style. Only "risk capital" should be used for trading and only those with sufficient risk capital should consider trading. I am not a licensed financial advisor nor do I give out financial advice. You assumes full risk and responsibility for their trading activity. Past performance is not indicative of future results. Individual results will vary due to a variety of market and timing conditions.
NYSE:TEVALong
by ZacharyHogan